Results 201 to 210 of about 102,161 (305)

Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations

British Journal of Clinical Pharmacology, EarlyView.
Aims Voriconazole is extensively metabolized via cytochrome P450 (CYP) enzymes, predominantly CYP2C19 and CYP3A4. Drugs influencing the activity or expression of CYP enzymes can cause clinically relevant changes in the metabolism and voriconazole exposure. Metamizole is known to induce CYP3A4 and CYP2C19.
Simone D. Baan, Daan J. Touw, Marjolijn N. Lub‐de Hooge, Thijs H. Oude Munnink   +3 more
wiley   +1 more source

Non-Respiratory Extracellular Electron Transfer Competes with Nitrogenase for Electrons in Rhodopseudomonas Palustris. [PDF]

Adv Sci (Weinh)
Liu X, Qi P, Fan W, Liu W, Li X, Nie Y, Wu XL.   +6 more
europepmc   +1 more source

The porphyrin of component c of cytochrome and its relationship to other porphyrins

, 1930
Robert D. Hill, D. Keilin
openalex   +1 more source

Approaches to repurposing reverse transcriptase antivirals in cancer

British Journal of Clinical Pharmacology, EarlyView.
This review highlights the role of reverse transcriptase (RT) inhibition in cellular regulation associated with non‐terminal repeat retrotransposons and endogenous retroviruses. Based on their pleiotropic characteristics, RT inhibitors (RTIs) are discussed as potential anticancer agents.
Richard Head, Saiful Islam, Jennifer H. Martin   +2 more
wiley   +1 more source

Cytochrome b5 occurrence in giant and other viruses belonging to the phylum Nucleocytoviricota. [PDF]

Npj Viruses
Lamb DC, Goldstone JV, Belhaouari DB, Andréani J, Farooqi A, Allen MJ, Kelly SL, La Scola B, Stegeman JJ.   +8 more
europepmc   +1 more source

Real‐world population pharmacokinetics of tezacaftor‐ivacaftor in children with cystic fibrosis: The SYM‐CF study

British Journal of Clinical Pharmacology, EarlyView.
Aims The clinical effectiveness of tezacaftor‐ivacaftor in children with cystic fibrosis (cwCF) varies; some patients respond while others do not or have adverse effects. The pharmacokinetics (PK) of tezacaftor‐ivacaftor are inadequately published, especially in children.
Steffie E. M. Vonk, Suzanne W. J. Terheggen‐Lagro, Eric G. Haarman, Hettie M. Janssens, Anke‐Hilse Maitland–van der Zee, E. Marleen Kemper, Ron A. A. Mathôt, on behalf of the Amsterdam Mucociliary Clearance Disease (AMCD) research group   +7 more
wiley   +1 more source

Periplasmic electron transfer network in Geobacter sulfurreducens revealed by biomolecular interaction studies. [PDF]

Protein Sci
Ferreira MR, Morgado L, Salgueiro CA.
europepmc   +1 more source

Iron and the Synthesis of Cytochrome C3

, 1956
J. R. Postgate
openalex   +1 more source

Artificial intelligence modelling of tyrosine kinase inhibitors at risk of malabsorption and bioavailability‐enhancing strategies

British Journal of Clinical Pharmacology, EarlyView.
Aims The study aims to predict and improve the absorption of tyrosine kinase inhibitors (TKIs) in patients with malabsorption issues, particularly those who have undergone bariatric surgery or are using proton‐pump inhibitors. The research involves 2 main components: the development of an artificial intelligence (AI) model to identify TKIs that are ...
Daan W. Huntjens, Olivier J. M. Béquignon, Stefanie D. Krens, Mark Löwenberg, Martine E. D. Chamuleau, Remco J. Molenaar, Anita M. G. Kramers, Marianne A. Kuijvenhoven, Imke H. Bartelink   +8 more
wiley   +1 more source

Isolation and characterization of <i>Sporomusa carbonis</i> sp. nov.: a carboxydotrophic hydrogenogen in the genus of <i>Sporomusa</i> isolated from a charcoal-burning pile. [PDF]

Int J Syst Evol Microbiol
Böer T, Rosenbaum FP, Eysell L, Müller V, Daniel R, Poehlein A.   +5 more
europepmc   +1 more source